论文部分内容阅读
目的:观察重组人血管内皮抑制素(恩度)联合GP方案治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法:经病理学检查确诊的38例ⅢB期和ⅠV期的NSCLC患者,包括鳞癌15例,腺癌21例,腺磷癌2例,均采用恩度加GP方案化疗。恩度剂量为15 mg/次,加入生理盐水500 mL中静滴3～4 h,第1～14天连续给药。GP方案为吉西他滨(GEM)1 000 mg/m2第1、8天,DDP 25mg/m2第1～3天给药,所有患者至少完成2个周期。根据WHO疗效评定及毒副反应分级标准,观察近期疗效、1年生存率、疾病进展时间及毒副反应。结果:38例NSCLC患者中,获得CR1例(2.63%),PR16例(42.1%),SD11例(28.9%),PD10例(26.37%)。中位TTP为4.3个月,1年生存率为15/38(39.5%)。治疗毒副反应主要有白细胞减少、血小板减少、恶心呕吐、肌肉关节疼痛和心血管毒性等。结论:恩度联合GP方案治疗晚期NSCLC的近期客观疗效较高,且安全性较好。
Objective: To observe the efficacy and side effects of recombinant human endostatin (Endostar) combined with GP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: Thirty-eight NSCLC patients with stage ⅢB and ⅠV diagnosed by pathology, including 15 cases of squamous cell carcinoma, 21 cases of adenocarcinoma and 2 cases of adenocarcinoma, were treated with entecavir GP regimen. Endure dose of 15 mg / time, added 500 mL of normal saline intravenous infusion of 3 ~ 4 h, 1 to 14 days of continuous administration. The GP regimen was gemcitabine (GEM) 1 000 mg / m2 on day 1 and day 8, and DDP 25 mg / m2 on day 1 to day 3. All patients completed at least 2 cycles. According to the WHO efficacy evaluation and classification criteria of toxic and side effects, observe the short-term efficacy, 1-year survival rate, disease progression time and side effects. Results: Of the 38 patients with NSCLC, CR1 (2.63%), PR16 (42.1%), SD11 (28.9%) and PD10 (26.37%) were obtained. The median TTP was 4.3 months and the 1-year survival rate was 15/38 (39.5%). The main side effects of treatment are leukopenia, thrombocytopenia, nausea and vomiting, muscle and joint pain and cardiovascular toxicity. Conclusion: Endood combined with GP regimen in the treatment of advanced non-small cell lung cancer (NSCLC) has higher objective efficacy and better safety.